Study ID | Sample size (I/C) | Gender (M/F) | Age | Intervention Group | Controlled Group | Syndrome Differentiation | Course of Treatment | Following-up | Outcomes | ||
---|---|---|---|---|---|---|---|---|---|---|---|

HAMD Mean score (SD) |
Effective Rate (events/total) | Adverse Effect | |||||||||

Depression | |||||||||||

Cheng XY 2007 [7] | 33/30 |
I:18/15; C:16/14 |
I:37.1 ± 7.6; C:36.7 ± 8.7 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | Y | 6 weeks | N | 6.32(2.33) vs 7.01(3.45) | NR |
I: somnolence, dry mouth and sleepy; C: insomnia, blurred vision, nausea, headache. (Case unknown) |

Lin B 2011 [8] | 30/30 |
I:13/17; C:15/15 |
I:52.13 ± 4.31; C:50.43 ± 4.80 | Chai Hu Shu Gan San | Fluoxetine | Y | 20 days | N | 11.53(7.41) vs 13.23(6.99) | 26/30 vs 5/30 | NR |

Liu YY 2012 [9] | 31/32 |
I:11/19; C:12/20 |
I:40.5 ± 9.9; C:36.6 ± 15.0 | Chai Hu Shu Gan San + Venlafaxine | Venlafaxine | Y | 4 weeks | N | 5.9(4.6) vs 8(5.6) | NR | NR |

Wang RC 2013 [10] | 40/40 |
I:18/22; C:21/19 |
I:33.6 ± 10.75; C:34.70 ± 11.23 | Chai Hu Shu Gan San | Paroxetine | Y | 6 weeks | N | 7.21(4.23) vs 7.52(3.79) | 33/40 vs 34/40 |
I: slight headache, tiredness,constipation, sweat, bitter taste; C: dry mouth, constipation, excitement and agitation, insomnia, dizziness, headache, palpitation, quiver, nausea, vomit, sexuality descent, ejaculation inhibition, female sexual lack. (Case unknown) |

Shao XQ 2016 [11] | 15/13 |
I:8/7; C:7/6 |
I:37.4 ± 7.53; C:36.7 ± 7.61 | Chai Hu Shu Gan San | Fluoxetine | Y | 6 weeks | 6 months | 9.51(4.84) vs 10.24(4.01) | 14/15 vs 12/13 | No adverse effect reported in intervention group;Nausea, anorexia, headache, sexual dysfunction reported in control group (Case unknown) |

Gu XX 2016 [12] | 30/30 |
I:18/12 C:16/14 |
I:33.1 ± 14.4 C:32.8 ± 17.1 | Chai Hu Shu Gan San + Mirtazapine | Mirtazapine | N | 8 weeks | N | 7.82(1.56) vs 15.88 (1.42) | 27/30 vs 24/30 | Appetite increased, weight gain, edema, nausea, dry mouth, sleep disorders (Case unknown) |

Hu J 2015 [13] | 48/48 |
I:20/28 C:22/26 |
I:38.56 ± 12.23 C:39.89 ± 11.83 | Chai Hu Shu Gan San | Paroxetine | N | 6 weeks | N | 9.65(3.44) vs C:8.98(4.32) | 43/48 vs 42/48 | NR |

Liu CY 2015 [14] | 35/34 | I:21/14C:19/15 |
I:49.12 ± 7.64 C:48.46 ± 7.25 | Chai Hu Shu Gan San + Amitriptyline | Amitriptyline | Y | 3 months | N | 4.83(1.37) vs 4.79(1.02) | 33/35 vs 28/34 | constipation (I = 1 vs C = 7/34); dry mouth (I = 0 vs C = 4); dizzy(I = 1 vs C = 5);electrocardiographic abnormality (I = 1 vs C = 6) |

Deng SZ 2012 [15] | 53/48 |
I:28/25; C:23/25 | NA | Chai Hu Shu Gan San + Citalopram | Citalopram | Y | 8 weeks | N | 6.07(1.86) vs 9.38(2.27) | 49/53 vs 37/48 | NR |

Song YM 2011 [16] | 30/30 |
I:11/19; C:12/18 |
I:46.5 ± 6.3; C:45.3 ± 7.2 | Chai Hu Shu Gan San | Fluoxetine | Y | 4 weeks | N | 14.8(3.3) vs 17.6(2.8) | 28/30 vs 24/30 | NR |

Fan QL 2008 [17] | 70/35 |
I:28/42; C:13/22 |
I:67.5; C:67.5 | Chai Hu Shu Gan San | Paroxetine | Y | 3 months | N | NR | 69/70 vs 29/35 | NR |

Deng GQ 2013 [18] | 30/30 |
I:13/17; C:12/18 |
I:38.5 ± 10.4; C:40.2 ± 12.1 | Chai Hu Shu Gan San | Paroxetine | Y | 6 weeks | N | 8.9(3.5) vs 9.7(2.8) | 24/30 vs 22/30 | NR |

Wang L 2012 [19] | 30/30 |
I:12/18; C:14/16 | NA | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | Y | 4 weeks | N | NR | 28/30 vs 25/30 | Insomnia, mental tension, nausea, headache (C = 9 vs I = 3) |

Post-stroke Depression | |||||||||||

Chang XH 2010 [20] | 50/50 |
I:31/19; C:28/22 |
I:42–74; C:45–75 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | Y | 28 days | N | 10.24(3.4) vs 14.2(2.7) | 48/50 vs 41/50 | NR |

Chen HH 2013 [21] | 47/47 |
I:30/17; C:29/18 |
I:67 ± 4; C:66 ± 5 | Chai Hu Shu Gan San | Fluoxetine | N | 4 weeks | N | 5.82(1.56) vs 6.21(1.38) | 43/47 vs 42/47 | Nausea (I = 1 vs C = 14), nodal tachycardia (I = 0 vs C = 5), stomach discomfort (I = 2 vs C = 15), dry mouth (I = 2 vs C = 18), somnolence (I = 1 vs C = 15); |

Cui Y 2016 [22] | 30/30 |
I:18/12; C:16/14 |
I:52.23 ± 9.90; C:50.73 ± 10.52 | Chai Hu Shu Gan San + Escitalopram Oxalate Tablets | Escitalopram Oxalate Tablets | Y | 6 weeks | N | 8.67(4.97) vs 12.4(6.97) | NR | no apparent adverse effect in both group. |

He XM 2007 [23] | 36/18 |
I:21/15; C:11/7 |
I:53.24 ± 6.31; C:54.36 ± 4.42 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | N | 60 days | N | 16.41(2.56) vs 22.06(3.35) | 32/36 vs 11/18 | digestive discomfort (I = 8 vs C = 10), vegetative nerve functional disturbance (I = 10 vs C = 9); |

Huang WX 2010 [24] | 32/31 |
I:17/15; C:16/15 |
I:65 ± 4.6; C:61 ± 5.3 | Chai Hu Shu Gan San + Deanxit | Deanxit | Y | 8 weeks | N | 15.6(4.4) vs 16.2(4.9) | NR |
I; dizziness (2 cases), constipation (1 cases); C: No adverse effect |

Huang YS 2012 [25] | 39/39 |
I:22/17; C:20/19 | I:62.51 ± 7.47;C:61.93 ± 7.82 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | Y | 3 months | N | 9.57(2.11) vs 13.08(2.58) | 35/39 vs 32/39 |
I: No adverse effect; C: 6 cases with dry mouth, nausea, vomit, appetite reduced, insomnia, headache, tiredness. |

Lian Z 2009 [26] | 30/30 |
I:17/13; C:16/14 |
I:56.20 ± 18.6; C:54.6 ± 17.5 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | N | 60 days | N | 6.21(2.53) vs 12.1(1.25) | 26/30 vs 24/30 | gastrointestinal discomfort (I = 6 vs C = 14), Autonomic nerve dysfunction (I = 7 vs C = 16) |

Wang GL 2009 [27] | 66/66 |
I:24/40; C:28/38 |
I:63.5 ± 2.3; C:64.5 ± 3.4 | Chai Hu Shu Gan San + Paroxetine | Paroxetine | Y | 6 weeks | N | 7.2(2.1) vs 10.1(1.7) | 62/66 vs 52/66 | NR |

Ji XL 2013 [28] | 30/30 |
I:18/12 C:17/13 | NA | Chai Hu Shu Gan San | Fluoxetine | Y | 30 days | N | 9.1(3.2) vs 13.3(3.5) | 25/30 vs 19/30 | NR |

Zhang FH 2013 [29] | 40/40 |
I:18/22 C:16/24 |
I:66.3; C:65.8 | Chai Hu Shu Gan San + Deanxit | Deanxit | Y | 6 weeks | N | 14.2(2.1) vs 17.3(2.6) | 36/40 vs 31/40 | NR |

Ren MJ 2015 [30] | 36/36 | 41/31 | 58.6 ± 2.1 | Chai Hu Shu Gan San | Fluoxetine | Y | 30 days | N | 8.2(2.6) vs 14.1(2.8) | 35/36 vs 30/36 | Dry mouth, nausea, anorexia, fatigue (I = 0 vs C = 4) |

Postnatal Depression | |||||||||||

Zhao XP 2006 [31] | 45/42 |
I:0/45; C:0/42 |
I:29.04 ± 3.99; C:29.12 ± 4.26 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | Y | 4 weeks | N | 9.18(5.72) vs 11.36(5.73) | 43/45 vs 39/42 | Nausea, appetite descent, anxiety, somnipathy, quiver (Case unknown). |

Zhao Y 2016 [32] | 41/42 |
I:0/41; C:0/42 |
I:28.94 ± 5.03; C:30.12 ± 4.3 | Chai Hu Shu Gan San + Fluoxetine | Fluoxetine | N | 8 weeks | N | 8.31(2.05) vs 13.96(2.16) | NR | Dry mouth, dizziness, nausea, tiredness, somnolence, quiver (I = 3 vs C = 10) |

Cancer and Depression | |||||||||||

Fang XH 2013 [33] | 45/45 |
I:17/28; C:24/21 |
I:42.3 ± 18.1; C:47.6 ± 16.9 | Chai Hu Shu Gan San | Fluoxetine | N | 6 weeks | N | 11.78(3.21) vs 13.98(2.12) | 38/45 vs 34/45 | Dry mouth (I = 2 vs C = 3), constipation (I = 2 vs C = 0), dizziness and headache (I = 3 vs C = 2),insomnia (I = 4 vs C = 1), gastrointestinal dysfunction (I = 7 vs C = 2), blurred vision (I = 2 vs C = 0) |

Epilepsy and Depression | |||||||||||

Huang XB 2015 [34] | 62/60 | 64/58 | 37.28 ± 7.29 | Chai Hu Shu Gan San | Paroxetine | N | 12 weeks | N | 17.68(1.95) vs 22.12(1.9) | 41/57 vs 25/54 | NR |

Chronic Pelvic Inflammation and Depression | |||||||||||

Li L 2006 [35] | 38/36/38 |
I:0/38; C1:0/36; C2:0/38 | N/A | Chai Hu Shu Gan San | C1: Paroxetine; C2: No Intervention | N | 6 weeks | N | 17.71(3.91) vs C1:18.55(4.51); C2: 22.00(3.91) | 34/38 vs C1:28/36; C2:18/38 | NR |

Post-PCI and Depression | |||||||||||

Wang YT 2016 [36] | 30/30 | NA | NA | Chai Hu Shu Gan San | Deanxit | N | 4 weeks | N | 15.73(6.05) vs 14.77(6.84) | 25/30 vs 23/30 | NR |

COPD and Depression | |||||||||||

Yang G 2011 [37] | 40/40 |
I:24/16; C:22/18 |
I:62.37 ± 6.78; C:63.6 ± 7.25 | Chai Hu Shu Gan San | No Intervention | N | 4 weeks | N | 14.59(1.12) vs 20.15(1.08) | 34/40 vs 20/40 | NR |

Parkinson and Depression | |||||||||||

Ma YZ 2011 [38] | 36/32 | NA | NA | Chai Hu Shu Gan San + Sertraline Hydrochloride | Sertraline Hydrochloride | Y | 4 weeks | N | 9.2(3.6) vs 12.3(5.4) | NR | NR |

Zhou R 2016 [39] | 36/36 |
I:18/18; C:16/20 | NA | Chai Hu Shu Gan San + Duloxetine | Duloxetine | Y | 4 weeks | N | 15.96(3.96) vs 20.28(3.56) | NR | Nausea (I = 2 vs C = 2), headache (I = 0 vs C = 1) |

Yang MJ 2010 [40] | 30/30 | I:18/12; C:17/13 |
I:62 ± 6.53; C:62.13 ± 5.92 | Chai Hu Shu Gan San + Paroxetine | Paroxetine | Y | 8 weeks | N | 9.02(1.24) vs 13.12(2.72) | 27/30 vs 21/30 | Dry mouth (I = 2 vs C = 5); fatigue (I = 1 vs C = 3); Nausea (I = 2 vs C = 3); poor appetite (I = 4 vs C = 5); insomnia (I = 2 vs C = 5); constipation (I = 2 vs C = 5) |

Piman syndrome and Depression | |||||||||||

Qiu ZJ 2012 [41] | 36/36/36 |
I:17/19; C1:16/20; C2:17/19 |
I:36.17 ± 13.29; C1:36.17 ± 11.29; C2:38.83 ± 11.94 | Chai Hu Shu Gan San |
C1:Deanxit; C2: No Intervention | N | 6 weeks | N | 6.42(3.68) vs C1:5.42(4.14); C2:16.03(4.34) | NR | Mouth odor, nausea, vomit, inappetence, gastrointestinal dysfunction, diarrhea, constipation in three groups, (Case unknown) |

Cerebrovascular disease and Depression | |||||||||||

Yao K 2013 [42] | 38/38 |
I:20/18; C:19/19 |
I:65.27 ± 8.35; C:66.31 ± 7.94 | Chai Hu Shu Gan San + Mirtazapine | Mirtazapine | Y | 4 weeks | N | 12.53(3.17) vs 15.87(3.62) | 34/38 vs 30/38 | Dry mouth, nausea, constipation (Case unknow) |

Shang GM 2014 [43] | 29/29 |
I:17/12; C:16/13 | I:63.38 ± 10.21; C:62.91 ± 9.83 | Chai Hu Shu Gan San | Fluoxetine | N | 4 weeks | N | NR | 27/29 vs 23/29 | NR |

Gastroesophageal Reflux Disease and Depression | |||||||||||

Zheng YJ 2016 [44] | 43/42 |
I:18/25; C:17/25 |
I:32.3 ± 12.6; C:44.2 ± 7.4 | Chai Hu Shu Gan San | No Intervention | N | 8 weeks | N | 9.2(1.3) vs 14.3(1.8) | 40/43 vs 32/42 | Nausea (I = 1 vs C = 5), dry mouth (I = 0 vs C = 2), dizziness (I = 0 vs C = 4) |

Coronary heart disease and Depression | |||||||||||

Liu YH 2014 [45] | 25/24 |
I:14/11; C:13/11 |
I:60.7 ± 13.6; C:56.8 ± 10.2 | Chai Hu Shu Gan San | No Intervention | N | 4 weeks | N | NR | 19/25 vs 9/24 | No adverse effect reported in both groups |

Rheumatoid arthritis and Depression | |||||||||||

Chen PY 2015 [46] | 34/34 | NA | NA | Chai Hu Shu Gan San | Paroxetine | N | 6 weeks | N | 10.68(6.83) vs 19.31(7.69) | NR | NR |

Diabetes and Depression | |||||||||||

Yang YL 2013 [47] | 40/38 | I:18/22; C:15/23 | I:38.70 ± 11.10; C:37.5 ± 11.2 | Chai Hu Shu Gan San | Paroxetine | Y | 3 months | N | 14.12(7.84) vs 22.69(11.66) | 38/40 vs 28/38 | NR |

Cardiac neurosis and Depression | |||||||||||

Pei GX 2013 [48] | 60/60 | I:18/42; C:24/36 | I:42.58 ± 6.12; C:44.32 ± 4.58 | Chai Hu Shu Gan San + Deanxit | Deanxit | Y | 8 weeks | N | 11.42(3.45) vs 13.68(2.74) | 57/60 vs 53/60 | NR |